uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
U.S. GoldMining provided an operational update on infrastructure developments in the West Susitna Mineral District that benefit its Whistler Gold-Copper Project. Key updates include the U.S. Army Corps of Engineers initiating an expedited emergency permitting process for the state-led West Susitna Access Road and a $249 million federal grant awarded to complete the Port MacKenzie rail extension.
BioLargo's subsidiary, Clyra Medical Technologies, provided a commercial update following the SAWC Fall 2026 conference, noting that its ViaCLYR wound irrigation solution is currently undergoing clinical evaluations and approval processes with several U.S. healthcare systems. The company has established a distribution network covering approximately 85% of the U.S. market through partners like Advanced Solution and Spartan Medical.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions (AITX) launched a marketing campaign for its 'SARA' agentic AI security platform, featuring a simulated job interview with CEO Steve Reinharz. The campaign aims to promote the AI's capabilities in incident management and escalation to security services and remote monitoring providers.
QVC Group, Inc. filed its quarterly post-confirmation operating report with the U.S. Bankruptcy Court for the Southern District of Texas following its emergence from Chapter 11 on August 6, 2026. The report covers the period from the plan's effective date through September 30, 2026, as required by the Bankruptcy Code. The filing is a routine post-restructuring compliance update and does not contain audited financial statements or a formal GAAP income statement.
Vistagen Therapeutics implemented a 31% reduction in its workforce to reduce operating expenses and preserve capital for its Phase 3 development of fasedienol. The company expects to incur approximately $1.0 million in one-time severance and termination costs while realizing annual savings of approximately $3.2 million in salary and benefits.
Dauch Corp announced preliminary Q3 2026 results and updated its full-year 2026 guidance, citing macro headwinds including customer production volatility and rising energy costs. The company expects a Q3 net loss of $42M to $47M and lowered its full-year Adjusted EBITDA target to a range of $1.350B to $1.375B.
Vulcan Materials' subsidiary, Calmat Co., received an imminent danger order from the Mine Safety and Health Administration (MSHA) at its Lexington Quarry in California. The order related to fall hazards during maintenance; no injuries occurred and the company took immediate corrective action to terminate the order.
Precision Optics Corporation entered into a new one-year lease agreement with Equity Assets, Inc. for its existing 12,292 square foot facility in Gardner, Massachusetts. The lease commenced July 1, 2026, with monthly rent starting at $13,316.33 and includes two one-year extension options.
Pacific Coast Oil Trust announced there will be no cash distribution for October 2026 based on net profits generated during August 2026. The Trust remains in a state of mandatory dissolution as annual proceeds have fallen below the $2.0 million threshold for two consecutive years. Additionally, the Trust provided an update on ongoing derivative litigation in Texas regarding the deduction of asset retirement obligations.
United States Commodity Index Funds Trust Business Update
United States Commodity Index Funds Trust issued monthly account statements for its USCI and CPER series for the month ended September 30, 2026. The filing provides detailed income statements and changes in net asset value for each fund as required by the Commodity Exchange Act.
United States Brent Oil Fund, LP issued its monthly account statement for September 2026, reporting a net income of $76.1 million. The fund's Net Asset Value (NAV) ended the period at $642.7 million, or $60.07 per share, reflecting realized trading gains on commodity futures partially offset by unrealized losses.
United States 12 Month Natural Gas Fund Business Update
United States 12 Month Natural Gas Fund, LP issued its monthly account statement for September 2026, reporting a net loss of $494,246. The fund's Net Asset Value (NAV) ended the period at $15,985,679, or $5.71 per share, driven primarily by realized and unrealized trading losses on commodity futures.
United States Gasoline Fund, LP issued its monthly account statement for September 2026, reporting net income of $23.56 million. The fund's Net Asset Value (NAV) ended the month at $190.16 million, or $146.28 per share, following additions of 200,000 shares and withdrawals of 50,000 shares.
United States Natural Gas Fund, LP (UNG) issued its monthly account statement for September 2026, reporting a net loss of $0.52 million. The fund's net asset value (NAV) ended the month at $469.86 million, or $10.41 per share, following significant share withdrawals totaling $157.4 million.
United States Oil Fund, LP (USO) issued its monthly account statement for September 2026, reporting net income of $179.97 million. The fund's Net Asset Value (NAV) ended the month at $1.65 billion, or $145.44 per share, following $940.7 million in share additions and $1.26 billion in withdrawals.
Green Plains Inc. entered into a Tax Credit Purchase Agreement to monetize Section 45Z Clean Fuel Production Tax Credits generated at its ethanol facilities during 2026. The company committed to deliver a minimum of $250 million and up to $325 million in credits to two institutional buyers at a market-based discount, with $140 million in cash proceeds expected in Q4 2026.
Moleculin Biotech has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML). The company remains on track to report comprehensive data from the 90-patient Part A population in the first quarter of 2027, which will inform dose selection for Part B of the trial.
Nelnet, Inc.'s wholly-owned subsidiary, Nelnet Bank, filed its quarterly Consolidated Reports of Condition and Income (Call Report) with the FDIC for the period ended September 30, 2026. The filing serves as a regulatory disclosure update for the bank's financial condition and operations, which are now publicly available on the FDIC website.
INVE Technologies announced a revision to its preliminary Q3 2026 financial results due to post-closing adjustments from an asset sale to Trackonomy Systems, Inc. The company now expects a preliminary net loss of $1.1 million to $1.3 million, compared to previously reported net income, while maintaining an expected cash balance of $87.1 million.
Dermata Therapeutics announced the enrollment of the first participant in a clinical trial for Tome Clearing Treatment, its once-weekly acne treatment. The company expects to launch this product commercially in the first half of 2027 as part of its strategic shift toward skincare products.
Jack Henry & Associates reported deconversion revenue of $17.9 million for the fiscal first quarter ended September 30, 2026. The company also provided an updated full-year fiscal 2027 deconversion revenue estimate of $30.0 million, noting that this revenue is typically generated when clients are acquired by other institutions.
Novavax earned a $125 million milestone payment from Sanofi following the dosing of the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union. The trial utilizes Novavax's Nuvaxovid COVID-19 component in combination with Sanofi's high-dose flu vaccine. Novavax expects to receive the payment by the first quarter of 2027 and remains eligible for further clinical and regulatory milestones.
Phunware CEO Dmitry Kroshka issued a shareholder letter outlining the 'Phunware 2.0' strategy to transition the company into an AI-enabled B2B intelligence platform for hospitality and healthcare. The update highlights the launch of an AI Concierge and Itinerary Planner, shifting the business model from simple wayfinding to a data-driven intent graph for property operators.
Partners Group Lending Fund, LLC reported its Net Asset Value (NAV) and portfolio statistics as of September 30, 2026. The Fund's aggregate NAV was approximately $322.1 million, with a total portfolio size of $542.4 million across 73 borrowers, primarily concentrated in First Lien/Unitranche loans (95.6%).
Digital Brands Group provided a corporate update announcing its decision to maintain its public listing while continuing to review inbound interest from investors. The company upgraded its Q4 cash flow forecast from its $165 million government contract to $4.7 million and reported strong performance from its AVO brand digital relaunch.
Fidelity Core Real Estate Fund released its monthly fact sheet for September 30, 2026, reporting a Net Asset Value (NAV) per share of $11.60 for Class I shares. The fund disclosed an annualized net total return of 8.84% since inception and a current annualized distribution rate of 4.50%.
Genasys Inc. announced preliminary unaudited financial results for its fiscal fourth quarter and full fiscal year 2026, reporting record performance. The company expects full-year revenue between $60.5M and $62.0M and adjusted EBITDA between $7.2M and $8.2M, driven by growth in its software business and the Puerto Rico Dams Early Warning System project.
Evolution Metals & Technologies Corp. (EM&T) has secured 754 metric tons of non-China sourced neodymium metal, including a 600-metric-ton contract with Senri Trading, to support its 2027 production goals. The company is also commissioning 57 containers of ULVAC equipment to expand its annual magnet production capacity from 1,000 to over 10,000 metric tons. These operational milestones are intended to support the company's 2027 revenue guidance of $400 million to $460 million.
Counterparty
Senri Trading
Term
through 2027
“There is no shortage of rare earth material. China is a net importer of rare earth ore, with approximately 60% of what it processes coming from outside China, and there is no shortage of investment in developing even more rare earth mines. What is in short supply, outside China, is commercial-scale magnet production and magnet materials producers.”
Azitra has amended its Phase 1/2 clinical trial protocol for ATR-04 to expand patient eligibility to include those with rashes caused by KRAS and MEK inhibitors, as well as NF1 patients. The company also shortened required washout periods for antibiotics and steroids to accelerate patient recruitment and enrollment for Cohort 2 of the study.